American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Identifieur interne : 001841 ( Main/Corpus ); précédent : 001840; suivant : 001842American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Auteurs : Ted R. Mikuls ; Sindhu R. Johnson ; Liana Fraenkel ; Reuben J. Arasaratnam ; Lindsey R. Baden ; Bonnie L. Bermas ; Winn Chatham ; Stanley Cohen ; Karen Costenbader ; Ellen M. Gravallese ; Andre C. Kalil ; Michael E. Weinblatt ; Kevin Winthrop ; Amy S. Mudano ; Amy Turner ; Kenneth G. SaagSource :
- Arthritis & rheumatology (Hoboken, N.J.) [ 2326-5205 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Advisory Committees (MeSH), Angiotensin Receptor Antagonists (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Antirheumatic Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Delivery of Health Care (MeSH), Delphi Technique (MeSH), Deprescriptions (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunosuppressive Agents (therapeutic use), Infection Control (MeSH), Janus Kinase Inhibitors (therapeutic use), Pandemics (prevention & control), Pneumonia, Viral (complications), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Rheumatic Diseases (complications), Rheumatic Diseases (drug therapy), Rheumatology (MeSH), SARS-CoV-2 (MeSH), Tumor Necrosis Factor Inhibitors (therapeutic use).
- MESH :
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Anti-Inflammatory Agents, Non-Steroidal, Antirheumatic Agents, Glucocorticoids, Hydroxychloroquine, Immunosuppressive Agents, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors.
- complications : Coronavirus Infections, Pneumonia, Viral, Rheumatic Diseases.
- drug therapy : Rheumatic Diseases.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- Adult, Advisory Committees, Betacoronavirus, COVID-19, Delivery of Health Care, Delphi Technique, Deprescriptions, Humans, Infection Control, Rheumatology, SARS-CoV-2.
Abstract
OBJECTIVE
To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic.
METHODS
A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included 2 rounds of asynchronous anonymous voting by e-mail and 3 webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.
RESULTS
The task force approved 77 initial guidance statements: 36 with moderate and 41 with high consensus. These were combined, resulting in 25 final guidance statements.
CONCLUSION
These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
DOI: 10.1002/art.41301
PubMed: 32349183
Links to Exploration step
pubmed:32349183Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.</title><author><name sortKey="Mikuls, Ted R" sort="Mikuls, Ted R" uniqKey="Mikuls T" first="Ted R" last="Mikuls">Ted R. Mikuls</name><affiliation><nlm:affiliation>University of Nebraska Medical Center, Omaha, Nebraska and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska.</nlm:affiliation></affiliation></author><author><name sortKey="Johnson, Sindhu R" sort="Johnson, Sindhu R" uniqKey="Johnson S" first="Sindhu R" last="Johnson">Sindhu R. Johnson</name><affiliation><nlm:affiliation>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fraenkel, Liana" sort="Fraenkel, Liana" uniqKey="Fraenkel L" first="Liana" last="Fraenkel">Liana Fraenkel</name><affiliation><nlm:affiliation>Berkshire Health Systems, Pittsfield, Massachusetts, and Yale University, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Arasaratnam, Reuben J" sort="Arasaratnam, Reuben J" uniqKey="Arasaratnam R" first="Reuben J" last="Arasaratnam">Reuben J. Arasaratnam</name><affiliation><nlm:affiliation>University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Baden, Lindsey R" sort="Baden, Lindsey R" uniqKey="Baden L" first="Lindsey R" last="Baden">Lindsey R. Baden</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Bermas, Bonnie L" sort="Bermas, Bonnie L" uniqKey="Bermas B" first="Bonnie L" last="Bermas">Bonnie L. Bermas</name><affiliation><nlm:affiliation>University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Chatham, Winn" sort="Chatham, Winn" uniqKey="Chatham W" first="Winn" last="Chatham">Winn Chatham</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation></affiliation></author><author><name sortKey="Cohen, Stanley" sort="Cohen, Stanley" uniqKey="Cohen S" first="Stanley" last="Cohen">Stanley Cohen</name><affiliation><nlm:affiliation>Metroplex Clinical Research Center, Dallas, Texas.</nlm:affiliation></affiliation></author><author><name sortKey="Costenbader, Karen" sort="Costenbader, Karen" uniqKey="Costenbader K" first="Karen" last="Costenbader">Karen Costenbader</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Gravallese, Ellen M" sort="Gravallese, Ellen M" uniqKey="Gravallese E" first="Ellen M" last="Gravallese">Ellen M. Gravallese</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Kalil, Andre C" sort="Kalil, Andre C" uniqKey="Kalil A" first="Andre C" last="Kalil">Andre C. Kalil</name><affiliation><nlm:affiliation>University of Nebraska Medical Center, Omaha.</nlm:affiliation></affiliation></author><author><name sortKey="Weinblatt, Michael E" sort="Weinblatt, Michael E" uniqKey="Weinblatt M" first="Michael E" last="Weinblatt">Michael E. Weinblatt</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Winthrop, Kevin" sort="Winthrop, Kevin" uniqKey="Winthrop K" first="Kevin" last="Winthrop">Kevin Winthrop</name><affiliation><nlm:affiliation>Oregon Health and Science University, Portland.</nlm:affiliation></affiliation></author><author><name sortKey="Mudano, Amy S" sort="Mudano, Amy S" uniqKey="Mudano A" first="Amy S" last="Mudano">Amy S. Mudano</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation></affiliation></author><author><name sortKey="Turner, Amy" sort="Turner, Amy" uniqKey="Turner A" first="Amy" last="Turner">Amy Turner</name><affiliation><nlm:affiliation>American College of Rheumatology, Atlanta, Georgia.</nlm:affiliation></affiliation></author><author><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G" last="Saag">Kenneth G. Saag</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32349183</idno><idno type="pmid">32349183</idno><idno type="doi">10.1002/art.41301</idno><idno type="wicri:Area/Main/Corpus">001841</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001841</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.</title><author><name sortKey="Mikuls, Ted R" sort="Mikuls, Ted R" uniqKey="Mikuls T" first="Ted R" last="Mikuls">Ted R. Mikuls</name><affiliation><nlm:affiliation>University of Nebraska Medical Center, Omaha, Nebraska and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska.</nlm:affiliation></affiliation></author><author><name sortKey="Johnson, Sindhu R" sort="Johnson, Sindhu R" uniqKey="Johnson S" first="Sindhu R" last="Johnson">Sindhu R. Johnson</name><affiliation><nlm:affiliation>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fraenkel, Liana" sort="Fraenkel, Liana" uniqKey="Fraenkel L" first="Liana" last="Fraenkel">Liana Fraenkel</name><affiliation><nlm:affiliation>Berkshire Health Systems, Pittsfield, Massachusetts, and Yale University, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Arasaratnam, Reuben J" sort="Arasaratnam, Reuben J" uniqKey="Arasaratnam R" first="Reuben J" last="Arasaratnam">Reuben J. Arasaratnam</name><affiliation><nlm:affiliation>University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Baden, Lindsey R" sort="Baden, Lindsey R" uniqKey="Baden L" first="Lindsey R" last="Baden">Lindsey R. Baden</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Bermas, Bonnie L" sort="Bermas, Bonnie L" uniqKey="Bermas B" first="Bonnie L" last="Bermas">Bonnie L. Bermas</name><affiliation><nlm:affiliation>University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Chatham, Winn" sort="Chatham, Winn" uniqKey="Chatham W" first="Winn" last="Chatham">Winn Chatham</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation></affiliation></author><author><name sortKey="Cohen, Stanley" sort="Cohen, Stanley" uniqKey="Cohen S" first="Stanley" last="Cohen">Stanley Cohen</name><affiliation><nlm:affiliation>Metroplex Clinical Research Center, Dallas, Texas.</nlm:affiliation></affiliation></author><author><name sortKey="Costenbader, Karen" sort="Costenbader, Karen" uniqKey="Costenbader K" first="Karen" last="Costenbader">Karen Costenbader</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Gravallese, Ellen M" sort="Gravallese, Ellen M" uniqKey="Gravallese E" first="Ellen M" last="Gravallese">Ellen M. Gravallese</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Kalil, Andre C" sort="Kalil, Andre C" uniqKey="Kalil A" first="Andre C" last="Kalil">Andre C. Kalil</name><affiliation><nlm:affiliation>University of Nebraska Medical Center, Omaha.</nlm:affiliation></affiliation></author><author><name sortKey="Weinblatt, Michael E" sort="Weinblatt, Michael E" uniqKey="Weinblatt M" first="Michael E" last="Weinblatt">Michael E. Weinblatt</name><affiliation><nlm:affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Winthrop, Kevin" sort="Winthrop, Kevin" uniqKey="Winthrop K" first="Kevin" last="Winthrop">Kevin Winthrop</name><affiliation><nlm:affiliation>Oregon Health and Science University, Portland.</nlm:affiliation></affiliation></author><author><name sortKey="Mudano, Amy S" sort="Mudano, Amy S" uniqKey="Mudano A" first="Amy S" last="Mudano">Amy S. Mudano</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation></affiliation></author><author><name sortKey="Turner, Amy" sort="Turner, Amy" uniqKey="Turner A" first="Amy" last="Turner">Amy Turner</name><affiliation><nlm:affiliation>American College of Rheumatology, Atlanta, Georgia.</nlm:affiliation></affiliation></author><author><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G" last="Saag">Kenneth G. Saag</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Arthritis & rheumatology (Hoboken, N.J.)</title><idno type="eISSN">2326-5205</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Advisory Committees (MeSH)</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>Delivery of Health Care (MeSH)</term><term>Delphi Technique (MeSH)</term><term>Deprescriptions (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Infection Control (MeSH)</term><term>Janus Kinase Inhibitors (therapeutic use)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Rheumatic Diseases (complications)</term><term>Rheumatic Diseases (drug therapy)</term><term>Rheumatology (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Tumor Necrosis Factor Inhibitors (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Antirheumatic Agents</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term><term>Immunosuppressive Agents</term><term>Janus Kinase Inhibitors</term><term>Tumor Necrosis Factor Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Advisory Committees</term><term>Betacoronavirus</term><term>COVID-19</term><term>Delivery of Health Care</term><term>Delphi Technique</term><term>Deprescriptions</term><term>Humans</term><term>Infection Control</term><term>Rheumatology</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included 2 rounds of asynchronous anonymous voting by e-mail and 3 webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The task force approved 77 initial guidance statements: 36 with moderate and 41 with high consensus. These were combined, resulting in 25 final guidance statements.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32349183</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2326-5205</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>Arthritis & rheumatology (Hoboken, N.J.)</Title><ISOAbbreviation>Arthritis Rheumatol</ISOAbbreviation></Journal><ArticleTitle>American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.</ArticleTitle><Pagination><MedlinePgn>1241-1251</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/art.41301</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic.</AbstractText><AbstractText Label="METHODS">A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included 2 rounds of asynchronous anonymous voting by e-mail and 3 webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.</AbstractText><AbstractText Label="RESULTS">The task force approved 77 initial guidance statements: 36 with moderate and 41 with high consensus. These were combined, resulting in 25 final guidance statements.</AbstractText><AbstractText Label="CONCLUSION">These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.</AbstractText><CopyrightInformation>© 2020, American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mikuls</LastName><ForeName>Ted R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0002-0897-2272</Identifier><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha, Nebraska and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sindhu R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0003-0591-2976</Identifier><AffiliationInfo><Affiliation>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraenkel</LastName><ForeName>Liana</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6148-610X</Identifier><AffiliationInfo><Affiliation>Berkshire Health Systems, Pittsfield, Massachusetts, and Yale University, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arasaratnam</LastName><ForeName>Reuben J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baden</LastName><ForeName>Lindsey R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bermas</LastName><ForeName>Bonnie L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatham</LastName><ForeName>Winn</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Metroplex Clinical Research Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costenbader</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravallese</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil</LastName><ForeName>Andre C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinblatt</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winthrop</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mudano</LastName><ForeName>Amy S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>American College of Rheumatology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saag</LastName><ForeName>Kenneth G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Rheumatol</MedlineTA><NlmUniqueID>101623795</NlmUniqueID><ISSNLinking>2326-5191</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079424">Tumor Necrosis Factor Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="N">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069340" MajorTopicYN="N">Deprescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="N">Rheumatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079424" MajorTopicYN="N">Tumor Necrosis Factor Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32349183</ArticleId><ArticleId IdType="doi">10.1002/art.41301</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.</Citation></Reference><Reference><Citation>Arthritis foundation. URL: https://www.arthritis.org/.</Citation></Reference><Reference><Citation>GHLF Creakyjoints. URL: https://creakyjoints.org/.</Citation></Reference><Reference><Citation>Global Healthy Living Foundation. URL: https://www.ghlf.org/.</Citation></Reference><Reference><Citation>Brook R. US Agency for Health Care Policy and Research Office of the Forum for Quality and Effectiveness in Health Care clinical practice guideline development: methodology perspectives. In: McCormick MS, Siegel R, editors. The RAND/UCLA appropriateness method. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1994: p. 59-70.</Citation></Reference><Reference><Citation>Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 1998;338:1888-95.</Citation></Reference><Reference><Citation>Shekelle PG, Chassin MR, Park RE. Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Int J Technol Assess Health Care 1998;14:707-27.</Citation></Reference><Reference><Citation>Hemingway H, Chen R, Junghans C, Timmis A, Eldridge S, Black N, et al. Appropriateness criteria for coronary angiography in angina: reliability and validity. Ann Intern Med 2008;149:221-31.</Citation></Reference><Reference><Citation>Kravitz RL, Laouri M, Kahan JP, Guzy P, Sherman T, Hilborne L, et al. Validity of criteria used for detecting underuse of coronary revascularization. JAMA 1995;274:632-8.</Citation></Reference><Reference><Citation>Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001;135:647-52.</Citation></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.</Citation></Reference><Reference><Citation>Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.</Citation></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases [review]. Nat Rev Rheumatol 2015;11:693-704.</Citation></Reference><Reference><Citation>Bichile T, Petri M. Prevention and management of co-morbidities in SLE. Presse Med 2014;43:e187-95.</Citation></Reference><Reference><Citation>Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:729-52.</Citation></Reference><Reference><Citation>Burner TW, Rosenthal AK. Diabetes and rheumatic diseases. Curr Opin Rheumatol 2009;21:50-4.</Citation></Reference><Reference><Citation>Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020;38:337-42.</Citation></Reference><Reference><Citation>Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): an overview for emergency clinicians. Pediatr Emerg Med Pract 2020;17:1-24.</Citation></Reference><Reference><Citation>Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19 [review]. Am J Hematol 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. How to protect yourself & others. 2020. URL: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. What to do if you are sick. May 2020. URL: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html.</Citation></Reference><Reference><Citation>American College of Rheumatology. COVID-19 practice and advocacy resources. May 2020. URL: https://www.rheumatology.org/Announcements/COVID-19-Practice-and-Advocacy#Telehealth.</Citation></Reference><Reference><Citation>Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017;105:11-7.</Citation></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.</Citation></Reference><Reference><Citation>Danser AH, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic. Hypertension 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Younes A, Samad N. Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011;16:730-41.</Citation></Reference><Reference><Citation>American Heart Association. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. March 2020. URL: https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician.</Citation></Reference><Reference><Citation>Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Tselios K, Koumaras C, Urowitz MB, Gladman DD. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. Semin Arthritis Rheum 2014;43:521-5.</Citation></Reference><Reference><Citation>De Vries-Bouwstra JK, Allanore Y, Matucci-Cerinic M, Balbir-Gurman A. Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis. J Rheumatol 2020;47:249-54.</Citation></Reference><Reference><Citation>FitzGerald GA. Misguided drug advice for COVID-19. Science 2020;367:1434.</Citation></Reference><Reference><Citation>US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. March 2020. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19.</Citation></Reference><Reference><Citation>Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829-38.</Citation></Reference><Reference><Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community. April 2020. URL: https://www.nice.org.uk/guidance/ng163.</Citation></Reference><Reference><Citation>Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.</Citation></Reference><Reference><Citation>Qin X, Qiu S, Yuan Y, Zong Y, Tuo Z, Li J, et al. Clinical characteristics and treatment of patients infected with COVID-19 in Shishou, China. Lancet 2020. URL: https://ssrn.com/abstract=3541147.</Citation></Reference><Reference><Citation>D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395:e30-1.</Citation></Reference><Reference><Citation>Lee N, Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31:304-9.</Citation></Reference><Reference><Citation>Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 2019;23:99.</Citation></Reference><Reference><Citation>Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2015;67:1671-8.</Citation></Reference><Reference><Citation>Chen D, Li H, Xie J, Zhan Z, Liang L, Yang X. Herpes zoster in patients with systemic lupus erythematosus: clinical features, complications and risk factors. Exp Ther Med 2017;14:6222-8.</Citation></Reference><Reference><Citation>Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 2016;42:157-76.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.</Citation></Reference><Reference><Citation>LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993;95:258-64.</Citation></Reference><Reference><Citation>Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med 2018;8:E15.</Citation></Reference><Reference><Citation>Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1157-60.</Citation></Reference><Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949. E-pub ahead of print.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Coronavirus (COVID-19) update: daily roundup. March 2020. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-30-2020".</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.</Citation></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-3.</Citation></Reference><Reference><Citation>US Food and Drug Administration. FDA drug shortages. April 2020. URL: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Hydroxychloroquine+Sulfate+Tablets%26st=c%26tab=tabs-4%26panels=0.</Citation></Reference><Reference><Citation>Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken) 2016;68:1295-302.</Citation></Reference><Reference><Citation>Geraldino-Pardilla L, Perel-Winkler A, Miceli J, Neville K, Danias G, Nguyen S, et al. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus 2019;28:862-7.</Citation></Reference><Reference><Citation>Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol 2014;26:118-23.</Citation></Reference><Reference><Citation>Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.</Citation></Reference><Reference><Citation>Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, et al, for the Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998;7:80-5.</Citation></Reference><Reference><Citation>Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Sears SP, Getz TW, Austin CO, Palmer WC, Boyd EA, Stancampiano FF. Incidence of sustained ventricular tachycardia in patients with prolonged QTc after the administration of azithromycin: a retrospective study. Drugs Real World Outcomes 2016;3:99-105.</Citation></Reference><Reference><Citation>Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. Biomed Res Int 2018;2018:1574806.</Citation></Reference><Reference><Citation>Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53-61.</Citation></Reference><Reference><Citation>Tudesq JJ, Cartron G, Riviere S, Morquin D, Iordache L, Mahr A, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders [review]. Autoimmun Rev 2018;17:115-24.</Citation></Reference><Reference><Citation>Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258-65.</Citation></Reference><Reference><Citation>Singh JA. Infections with biologics in rheumatoid arthritis and related conditions: a scoping review of serious or hospitalized infections in observational studies. Curr Rheumatol Rep 2016;18:61.</Citation></Reference><Reference><Citation>Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.</Citation></Reference><Reference><Citation>Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.</Citation></Reference><Reference><Citation>Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31.</Citation></Reference><Reference><Citation>Zhang N, Wilkinson S, Riaz M, Östör AJ, Nisar MK. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol 2012;30:962-71.</Citation></Reference><Reference><Citation>Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-ɑ agents. JAMA 2009;301:737-44.</Citation></Reference><Reference><Citation>Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017;69:1960-8.</Citation></Reference><Reference><Citation>Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease [review]. Nat Rev Rheumatol 2017;13:320.</Citation></Reference><Reference><Citation>Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.</Citation></Reference><Reference><Citation>Van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75:52-8.</Citation></Reference><Reference><Citation>Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.</Citation></Reference><Reference><Citation>Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis 2019;78:171-8.</Citation></Reference><Reference><Citation>Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.</Citation></Reference><Reference><Citation>Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, Wojdyla D, Pons-Estel GJ, Quintana R, et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus 2019;28:1101-10.</Citation></Reference><Reference><Citation>Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1667-73.</Citation></Reference><Reference><Citation>Favalli EG, Ingegnoli F, de Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! [review]. Autoimmun Rev 2020;102523.</Citation></Reference><Reference><Citation>Al Ghamdi M, Alghamdi KM, Ghandoora Y, Alzahrani A, Salah F, Alsulami A, et al. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016;16:174.</Citation></Reference><Reference><Citation>Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses 2013;5:1250-60.</Citation></Reference><Reference><Citation>De Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 2011;92:2542-8.</Citation></Reference><Reference><Citation>Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;20:400-2.</Citation></Reference><Reference><Citation>National Institutes of Health. Therapeutic options for COVID-19 currently under investigation. April 2020. URL: https://covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/.</Citation></Reference><Reference><Citation>Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. February 2020. URL: https://www.ser.es/wp-content/uploads/2020/03/TCZ-and-COVID-19.pdf.</Citation></Reference><Reference><Citation>McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;102537.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Efficacy and safety of emapalumab and anakinra in reducing hyperinflammation and respiratory distress in patients with COVID-19 infection. April 2020. URL: https://clinicaltrials.gov/ct2/show/NCT04324021.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Anti-IL6 treatment of serious COVID-19 disease with threatening respiratory failure (TOCIVID). April 2020. URL: https://www.clinicaltrials.gov/ct2/show/NCT04322773.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID-19 (TACOS). April 2020. URL: https://clinicaltrials.gov/ct2/show/NCT04306705.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. April 2020. URL: https://clinicaltrials.gov/ct2/show/NCT04315298.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Treatment of moderate to severe coronavirus disease (COVID-19) in hospitalized patients. April 2020. URL: https://clinicaltrials.gov/ct2/show/NCT04321993.</Citation></Reference><Reference><Citation>Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15-going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66:726-35.</Citation></Reference><Reference><Citation>Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14-going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719-25.</Citation></Reference><Reference><Citation>Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic [review]. Nat Rev Rheumatol 2020. E-pub ahead of print.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001841 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001841 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32349183
|texte= American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32349183" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |